Table 1 Composition of the basic CLL cohort (n = 198)
From: Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
Parameter | n (%) |
|---|---|
Sex (female/male) | 77/121 (38.9% / 61.1%) |
Age at diagnosis (median) | 62.4Â years |
Untreated at the time of analysis | 153 (77.3%) |
Time to first treatment (median; n = 182) | 30 months |
IGHV status (mutated/unmutated) | 79/119 (39.9% / 60.1%) |
Hierarchical cytogenetics (FISH) | |
 del(17p) | 28 (14.1%) |
 del(11q) | 45 (22.7%) |
 trisomy 12 | 18 (9.1%) |
 normal | 37 (18.7%) |
 del(13q) | 70 (35.4%) |
 Complex karyotype (≥ 3 changes; n = 169) | 47 (27.8%) |
 Highly complex karyotype (≥ 5 changes; n = 169) | 23 (13.6%) |
 ATM mutation > 10% VAF (n = 191) | 37 (18.9%) |
 TP53 mutation > 10% VAF | 40 (20.2%) |